An interventional study of Cosmed QuarkSpiro Dosimeter-Controlled Nebulizer and DeVilbiss 45 Handheld Nebulizer in Cough Reflex Sensitivity, sponsored by University of Montana. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by University of Montana · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Cough with a site in United States — 18 open to participants now, 21 under way, none of them phase 3. Cough · United States.
Among the 104 studies in Cough with a site in United States, this one is the 77th largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2026, is one of 32 with no phase, reaches primary completion later than 8 of the 20 other live ones, and was the 99th registered.
429 studies on the registry are indexed under Cough; 68 are open to participants now.
Browse Cough studies →18 of the 104 studies in Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Joseph C. Wu · Sites in United States
Ages 40+
University of California, San Diego · Sites in United States
Ages 18–89
Hyfe Inc · Sites in United States
Ages 21+
All Natural Medicine Clinic, LLC · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Cough studies recruiting now, 20 (44%) set no upper age limit and 14 (31%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 19 · Phase 3 12 · Phase 4 9
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 80 across 321 interventional studies indexed under Cough.
Median enrollment 63 across the 86 interventional studies, 65 across the 18 observational. Of the 76 that completed or were terminated, 35 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 104 have an industry lead sponsor. The 10 most frequent:
University of Montana is the lead sponsor of 28 studies on the registry; 11 are open to participants now.
University of Montana has 4 studies filed under Cough — fewer than ten, so there is no comparison to draw.
7 of the studies in Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT04790240All Natural Medicine Clinic, LLCMedical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) | 2026-12-30 |
| NCT06190171Vanderbilt University Medical CenterRespiratory Strength Training in Heart Transplant Recipients | 2027-02-01 |
| NCT07531901University of MontanaEvaluating the Feasibility and Reliability of Using Handheld Nebulizers to Conduct Cough Sensitivity Testing With Citric Acid | 2027-02-01 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 104 studies in Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective cough reflex sensitivity testing is typically restricted to specialized research laboratories due to reliance on expensive dosimeter-controlled aerosol delivery systems. This study evaluates the feasibility and reliability of a low-cost alternative method using a handheld nebulizer for citric acid cough challenge testing. Healthy adult participants will complete cough reflex sensitivity testing using both a standard dosimeter-controlled nebulizer system (Cosmed QuarkSpiro) and a handheld nebulizer (DeVilbiss 45). The study will compare cough threshold outcomes between methods to determine whether handheld nebulizer-based testing produces comparable and reproducible measurements.
Cough reflex sensitivity testing is widely used in respiratory research to quantify airway sensory responsiveness. Traditional testing protocols use dosimeter-controlled nebulizer systems to deliver precise concentrations of aerosolized tussive agents such as citric acid. However, these systems are costly and require specialized laboratory infrastructure, limiting access to objective cough testing in outpatient and community-based settings.
This study investigates the feasibility and reliability of using a commercially available handheld nebulizer as a low-cost alternative for cough reflex sensitivity testing. Healthy adult volunteers will undergo standardized cough challenge testing using citric acid delivered through two aerosol delivery systems: a laboratory dosimeter-controlled nebulizer (Cosmed QuarkSpiro) and a handheld nebulizer (DeVilbiss 45). The primary outcomes will be cough threshold measures (e.g., C2 and C5), defined as the citric acid concentration that elicits two or five coughs.
Participants will complete testing sessions using both delivery methods under controlled conditions. Findings from this proof-of-concept study will inform future research aimed at expanding access to objective cough assessment in clinical and community settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo cough reflex sensitivity testing using a dosimeter-controlled nebulizer system (Cosmed QuarkSpiro) to deliver aerosolized citric acid.
Device: Cosmed QuarkSpiro Dosimeter-Controlled Nebulizer
Participants will undergo cough reflex sensitivity testing using a handheld nebulizer (DeVilbiss 45) to deliver aerosolized citric acid.
Device: DeVilbiss 45 Handheld Nebulizer
Laboratory spirometry system equipped with a dosimeter-controlled nebulizer used to deliver standardized aerosolized citric acid during cough challenge testing.
Commercial handheld nebulizer used to deliver aerosolized citric acid during cough challenge testing.
Test-retest reliability of the concentration of citric acid that elicits two or more coughs (C2)
The test-retest reliability (Intraclass correlation coefficient) of the citric acid concentration required to elicit two coughs during cough challenge testing will be evaluated and compared for each testing method.
Time frame: Cough sensitivity testing to determine cough thresholds (C2) will be performed at each of four weekly study visits, with visits occurring every 7 days across a 4-week study period.
Test-retest reliability of the concentration of citric acid that elicits five or more coughs (C5)
The test-retest reliability (Intraclass correlation coefficient) of the citric acid concentration required to elicit five coughs during cough challenge testing will be evaluated and compared for each testing method.
Time frame: Cough sensitivity testing to determine cough thresholds (C5) will be performed at each of four weekly study visits, with visits occurring every 7 days across a 4-week study period.
Plan to share: Yes — De-identified individual participant data supporting the results reported in publications will be available upon reasonable request to the Principle Investigator following publication of study findings.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD and supporting information will be available as soon as one month after data are published and available for up to three years after publication.
Access criteria: Data will be shared with qualified investigators who provide a methodologically sound proposal and documentation of appropriate institutional approvals, where required. Data will be shared in a de-identified format consistent with institutional policies and applicable privacy protections. Due to the small sample size, additional safeguards may be implemented to prevent potential participant re-identification.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.
Of 79 non-industry interventional studies with no phase under Cough, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 6 months is below that.
Counting every sponsor, half of 87 studies reached it within 15 months; a quarter within 6 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Montana